heiDATA

Metrics

223,007 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Publication Year: 2023 File Type: Document

31 to 40 of 415 Results

Vardarli_Suppl Fig 32.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 67.4 KB - MD5: f88edd9d1434d2e7a485b0046ef138cc Suppl. Fig. 32. Funnel plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 33.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.7 KB - MD5: ca104b25c915d8cc5ed5279e61a82df1 Suppl. Fig. 33. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 34.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 70.6 KB - MD5: 443bc4569f1231d2a43fc5d8673c139d Suppl. Fig. 34. Galbraith plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 35.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.1 KB - MD5: ba984fd679c86b272e1d13f3d8ad2365 Suppl. Fig. 35. Funnel plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 36.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 66.8 KB - MD5: 556e803b091dfed445b705972e835632 Suppl. Fig. 36. Funnel plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 37.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.0 KB - MD5: de822d4b8ef9cacb467052fdc63730d2 Suppl. Fig. 37. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 38.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 71.3 KB - MD5: 1dd5eec104223934185b7fef6e56cc4d Suppl. Fig. 38. Galbraith plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 39.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.4 KB - MD5: 5bf15c23af6441a53ca79acff68d604c Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 3.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 81.2 KB - MD5: 5d7d92c2e8572e1ec23068a2ed383898 Suppl. Fig. 3. Forest plot for leave-one out meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 40.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 67.1 KB - MD5: 23a3912a62f8977ad3197d69d3b0cd41 Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 32.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 67.4 KB -

Suppl. Fig. 32. Funnel plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 33.pdf

Adobe PDF - 64.7 KB -

Suppl. Fig. 33. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 34.pdf

Adobe PDF - 70.6 KB -

Suppl. Fig. 34. Galbraith plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 35.pdf

Adobe PDF - 64.1 KB -

Suppl. Fig. 35. Funnel plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 36.pdf

Adobe PDF - 66.8 KB -

Suppl. Fig. 36. Funnel plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 37.pdf

Adobe PDF - 64.0 KB -

Suppl. Fig. 37. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 38.pdf

Adobe PDF - 71.3 KB -

Suppl. Fig. 38. Galbraith plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 39.pdf

Adobe PDF - 64.4 KB -

Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 3.pdf

Adobe PDF - 81.2 KB -

Suppl. Fig. 3. Forest plot for leave-one out meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 40.pdf

Adobe PDF - 67.1 KB -

Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications